GeneCapture

Executive Summary

GeneCapture is a US-based diagnostics company developing The CAPTURE Platform™, a portable, point-of-care system designed to rapidly identify pathogens and determine antibiotic susceptibility from raw samples such as blood or urine—all in under two hours without requiring a centralized lab, refrigeration, or extensive training. Founded in 2015 and headquartered in Huntsville, Alabama, the company aims to enable faster, targeted treatment decisions at the point of patient care, addressing critical needs in combating antimicrobial resistance and improving outcomes in both hospital and remote settings. While still in the development stage and lacking disclosed funding or revenue, GeneCapture’s technology holds promise for decentralized infectious disease testing, especially in low-resource environments. The platform’s potential to bypass traditional culture-based methods positions it as a disruptive solution in the diagnostics market, though it faces significant regulatory, technical, and commercialization hurdles.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance or CE Mark for initial assay30% success
• Q3 2026Pilot partnerships with health systems or government agencies50% success
• Q2 2026Series A or B funding round announcement60% success